Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
German diesel hits new records over Easter weekend - 2'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- 3Find the Native Culinary Customs: Local Flavors
- 4‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- 5Israel and Iran continue tit-for-tat attacks
- Flu cases are rising with a strain that makes older people sicker
- NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Vote In favor of Your Number one Game Control center
- In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- FDA proposes use of sunscreen ingredient popular in other countries
- Emergency services search for five people last seen in missing Jeep
- How does Spotify Wrapped calculate your listening age? What your number says about you.
- Figure out How to Adjust Your Handshake to Various Societies
